Dott. Giovanni Salamano Studio Medico

Dott. Giovanni Salamano Studio Medico Da tre generazioni ci occupiamo della salute dei Vercellesi, come Medici di Famiglia dal 1921 ad ogg

 New in the October 16, 2025, issue of NEJM: ⁣⁣Sentinel-Node Biopsy in Cervical Cancer (PHENIX phase 3 trial) ⁣⁣Telitaci...
18/10/2025

New in the October 16, 2025, issue of NEJM: ⁣

Sentinel-Node Biopsy in Cervical Cancer (PHENIX phase 3 trial) ⁣

Telitacicept for Systemic Lupus Erythematosus (18C010 phase 3 trial) ⁣

Gene Therapy for Adenosine Deaminase Deficiency ⁣

Mass Azithromycin Administration to Infants in Mali (LAKANA trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the October 9, 2025, issue of NEJM: ⁣⁣Baxdrostat Efficacy and Safety in Uncontrolled Hypertension (BaxHTN phase ...
15/10/2025

New in the October 9, 2025, issue of NEJM: ⁣

Baxdrostat Efficacy and Safety in Uncontrolled Hypertension (BaxHTN phase 3 trial)⁣

Nexiguran Ziclumeran in ATTR with Polyneuropathy⁣

Targeted Indoor Spraying to Prevent Aedes-Borne Diseases⁣

Permethrin-Treated Wraps for Prevention of Malaria⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the October 2, 2025, issue of NEJM: ⁣⁣Intravenous Rehydration for Severe Acute Malnutrition (GASTROSAM trial) ⁣⁣...
15/10/2025

New in the October 2, 2025, issue of NEJM: ⁣

Intravenous Rehydration for Severe Acute Malnutrition (GASTROSAM trial) ⁣

Medical Imaging and Pediatric Hematologic Cancer Risk ⁣

Olezarsen in Moderate Hypertriglyceridemia (Essence–TIMI 73b phase 3 trial)⁣

Clesrovimab to Prevent RSV Disease in Healthy Infants (CLEVER phase 2b–3 trial)⁣

Home-Based Care for Hypertension in South Africa (IMPACT-BP trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 BREAKING NEWSThe Nobel Assembly at Karolinska Institutet has decided to award the 2025 Nobel Prize in Physiology or Med...
08/10/2025

BREAKING NEWS
The Nobel Assembly at Karolinska Institutet has decided to award the 2025 Nobel Prize in Physiology or Medicine to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”

This year’s medicine laureates have discovered how the immune system is kept in check. The body’s powerful immune system must be regulated, or it may attack our own organs. Brunkow, Ramsdell and Sakaguchi have been awarded this year’s medicine prize for their groundbreaking discoveries concerning peripheral immune tolerance that prevents the immune system from harming the body.

The laureates identified the immune system’s security guards, regulatory T cells, which prevent immune cells from attacking our own body.

The laureates’ discoveries launched the field of peripheral tolerance, spurring the development of medical treatments for cancer and autoimmune diseases. This may also lead to more successful transplantations. Several of these treatments are now undergoing clinical trials.

Happy Punctuation Day. September 24 is International punctuation Day. It’s very important thinking to interpersonal comm...
30/09/2025

Happy Punctuation Day. September 24 is International punctuation Day. It’s very important thinking to interpersonal communications changes , that’s required by changes and introduction of new technologies to real world.

 New in the September 25, 2025, issue of NEJM: ⁣⁣Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) ⁣⁣A...
27/09/2025

New in the September 25, 2025, issue of NEJM: ⁣

Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) ⁣

Apixaban for Provoked Venous Thromboembolism (HI-PRO trial) ⁣

Measurable Residual Disease–Guided Therapy for CLL (FLAIR phase 3 trial) ⁣

Early Tirofiban after Thrombolysis for Stroke (ASSET-IT phase 3 trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 In 1938, physician–scientist Dorothy Andersen first described cystic fibrosis, a lethal disease in infants and children...
21/09/2025

In 1938, physician–scientist Dorothy Andersen first described cystic fibrosis, a lethal disease in infants and children characterized by pancreatic fibrosis with cyst formation and bronchiectasis, including thick, inspissated secretions that obstruct the airways. Cystic fibrosis has subsequently been classified as a generalized exocrinopathy involving numerous additional epithelial tissues, such as the liver, intestines, reproductive tract, and sweat glands. During the ensuing decades, palliative treatments became standard care and prolonged lives, but the pathogenic mechanism remained a mystery. The identification, in 1989, of the “causal” gene, CFTR, which encodes the cystic fibrosis transmembrane conductance regulator (CFTR), was a milestone, although whether the breakthrough would result in better treatments was unclear. Over time, Drs. Michael Welsh, Jesús González, and Paul Negulescu would elucidate the pathogenesis, advance pharmaceutical science in remarkable new directions, and provide a transformational therapy for the disease. Their achievements are recognized by the 2025 Lasker–DeBakey Clinical Medical Research Award. ⁣

Learn more about their work in the Clinical Implications of Basic Research article “Transformative Research in Cystic Fibrosis” by Eric J. Sorscher, MD, from and , at NEJM.org (link in bio). ⁣

 New in the September 18, 2025, issue of NEJM: ⁣⁣Aspirin for PI3K-Altered Localized Colorectal Cancer (ALASCCA phase 3 t...
21/09/2025

New in the September 18, 2025, issue of NEJM: ⁣

Aspirin for PI3K-Altered Localized Colorectal Cancer (ALASCCA phase 3 trial) ⁣

Orforglipron in Early Type 2 Diabetes (ACHIEVE-1 phase 3 trial)⁣

Oral Semaglutide in Adults with Overweight or Obesity (OASIS 4 phase 3 trial)⁣

Proportional-Assist Ventilation (PROMIZING trial)⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the September 11, 2025, issue of NEJM: ⁣⁣Aficamten or Metoprolol for Hypertrophic Cardiomyopathy (MAPLE-HCM phas...
21/09/2025

New in the September 11, 2025, issue of NEJM: ⁣

Aficamten or Metoprolol for Hypertrophic Cardiomyopathy (MAPLE-HCM phase 3 trial) ⁣

Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM phase 3 trial) ⁣

Multidomain Rehabilitation for Older Patients with MI (PIpELINe trial) ⁣

Marburg Virus Disease in Rwanda ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe.⁣

 New in the September 4, 2025, issue of NEJM: ⁣⁣Maridebart Cafraglutide for the Treatment of Obesity (MariTide phase 2 t...
21/09/2025

New in the September 4, 2025, issue of NEJM: ⁣

Maridebart Cafraglutide for the Treatment of Obesity (MariTide phase 2 trial) ⁣

Stem Cell–Derived Islets for Type 1 Diabetes (VX-880-101 FORWARD phase 1–2 study) ⁣

Benzathine Penicillin G Doses for Early Syphilis⁣

Monoclonal Antibodies in the Pathogenesis of HIT ⁣

Brief Report: Allogeneic Beta-Cell Transplantation ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

New in the September 4, 2025, issue of NEJM: ⁣

Maridebart Cafraglutide for the Treatment of Obesity (MariTide phase 2 trial) ⁣

Stem Cell–Derived Islets for Type 1 Diabetes (VX-880-101 FORWARD phase 1–2 study) ⁣

Benzathine Penicillin G Doses for Early Syphilis⁣

Monoclonal Antibodies in the Pathogenesis of HIT ⁣

Brief Report: Allogeneic Beta-Cell Transplantation ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. New in the September 4, 2025, issue of NEJM: ⁣

Maridebart Cafraglutide for the Treatment of Obesity (MariTide phase 2 trial) ⁣

Stem Cell–Derived Islets for Type 1 Diabetes (VX-880-101 FORWARD phase 1–2 study) ⁣

Benzathine Penicillin G Doses for Early Syphilis⁣

Monoclonal Antibodies in the Pathogenesis of HIT ⁣

Brief Report: Allogeneic Beta-Cell Transplantation ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the August 21/28, 2025, issue of NEJM: ⁣⁣Overall Survival with Nivolumab in Lung Cancer (CheckMate 816 phase 3 t...
21/09/2025

New in the August 21/28, 2025, issue of NEJM: ⁣

Overall Survival with Nivolumab in Lung Cancer (CheckMate 816 phase 3 trial)⁣

Elinzanetant for Symptoms from Endocrine Therapy (OASIS-4 phase 3 trial) ⁣

Molgramostim in Pulmonary Alveolar Proteinosis (IMPALA-2 phase 3 trial) ⁣

Adjuvant Cemiplimab in High-Risk Cutaneous SCC (C-POST phase 3 trial) ⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

 New in the August 14, 2025, issue of NEJM: ⁣⁣Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a tr...
21/09/2025

New in the August 14, 2025, issue of NEJM: ⁣

Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣

Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial)⁣

Lactated Ringer’s Solution versus Normal Saline (FLUID trial) ⁣

Risdiplam in Presymptomatic Spinal Muscular Atrophy (RAINBOWFISH phase 2 study)⁣

Visit NEJM.org for the latest medical research and tap the link in our bio to subscribe. ⁣

Indirizzo

Piazza Solferino N. 3
Vercelli
13100

Orario di apertura

Lunedì 17:00 - 19:00
Martedì 17:00 - 19:00
Mercoledì 10:00 - 12:00
Giovedì 10:00 - 12:00
Venerdì 17:00 - 19:00

Telefono

+393345713761

Sito Web

https://www.miodottore.it/

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Dott. Giovanni Salamano Studio Medico pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Dott. Giovanni Salamano Studio Medico:

Condividi

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

A little help to Health in rural town.

Da tre generazioni lo Studio Medico Salamano si occupa della salute de

i pazienti Vercellesi. Zona posta tra le metropoli di Torino e Milano esattamente a metà strada tra le due città più importanti del Nord Italia è famosa nel mondo agricolo per la presenza della risicoltura resa possibile da Camillo Benso Conte di Cavour, primo ministro del Regno Sabaudo che qui regnava. La presenza del fiume Po e dei suoi maggiori affluenti dalle Alpi che circondano il Piemonte ha reso possibile nei primi dell’800 la costruzione di canali che permettono una abbondante irrigazione di queste terre, prima paludose e bonificate dai Monaci Cistercensi nell’epoca Medioevale intorno al 1200 - 1300 fondando importanti Abazie che facevano capo all’Arcidiocesi di Vercelli. Proprio a causa della posizione immersa nella pianura padana e nel suo clima afoso d’estate e nebbioso d’inverno, questa regione ha una insolitamente elevata percentuale di pazienti sofferenti di osteopatie ( i cosiddetti Reumatismi ) e malattie infettive dell’apparato respiratorio. Recentemente con l’aumento della vita media grazie ai progressi principalmente in capo cardiovascolare si sta assistendo ad un aumento quasi esponenziale dei casi di neoplasie dell’albero respiratorio, dell’apparato gastroenterico e urinario. Il problema dell’inquinamento atmosferico è in questa zona particolarmente evidente per le scarse correnti di aria che possano pulire e rinnovare l’aria ed il puvuscolo atmosferico stagnante in questa regione nonostante sia a carattere rurale e non industriale come le vicine Torino e Milano. Un particolare evidente nel recente passato è la particolare incidenza di Leptospirosi dovuta alla presenza di acqua stagnante nelle risaie dove le contadine lavoravano a piedi scalzi. Tuttavia anche l’artrite reumatoide e le malattie reumatiche in genere hanno una elevata incidenza tanto che fino a pochi anni fa nell’’Ospedale Sant’Andrea di Vercelli era presente un reparto di Reumatologia ( uno dei pochi in Italia e purtroppo recentemente eliminato ). Per tali motivi prima mio nonno Giovanni Dott Salamano ( Nino ) poi mio padre Andre Dott Salamano ed infine il sottoscritto Giovanni Dott Salamano abbiamo dedicato la nostra ”vita“ alla cura ed allo studio delle malattie infettive ( Nonno Nino ), Reumatiche ( papà Andrea ) ed osteometaboliche ( il sottoscritto ), pur mantenendo l’attenzione sulla Medicina Generale che il Medico di Famiglia deve saper affrontare.